Plain-English translation of NCT06732388 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether , an antifungal medication, can help prevent esophageal cancer in people with a condition called Barrett's esophagus. Participants will receive either the medication or a placebo (a pill with no active ingredient) while undergoing standard endoscopic treatment to remove abnormal tissue. The goal is to see if this medication can help the esophagus heal faster and reduce the risk of cancer developing.
Barrett's esophagus is a condition where abnormal cells grow in the esophagus and can develop into cancer. While doctors treat it with a procedure called ablation (removing the abnormal tissue), this medication may help prevent the abnormal tissue from coming back or progressing to cancer.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication or a placebo, taken by mouth twice daily for 42 days at a time, for up to two cycles (about 3 months total). During the study, you will have standard endoscopic procedures to remove abnormal tissue, and you will also have blood draws and tissue biopsies taken. You'll be monitored for safety and to see how well the treatment is working, with follow-up appointments to check for any return of abnormal cells.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States